Oruka Therapeutics’ (ORKA) Buy Rating Reaffirmed at BTIG Research

Oruka Therapeutics (NASDAQ:ORKA)‘s stock had its “buy” rating restated by analysts at BTIG Research in a report issued on Monday,Benzinga reports. They currently have a $151.00 target price on the stock. BTIG Research’s price objective points to a potential upside of 73.98% from the company’s current price.

A number of other equities research analysts have also recently commented on the stock. Wall Street Zen cut shares of Oruka Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, June 13th. Piper Sandler restated an “overweight” rating and set a $180.00 price objective on shares of Oruka Therapeutics in a research report on Tuesday, June 2nd. Wedbush set a $165.00 target price on shares of Oruka Therapeutics in a research note on Monday, April 27th. Weiss Ratings lowered Oruka Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, June 30th. Finally, Guggenheim set a $200.00 price objective on Oruka Therapeutics and gave the stock a “buy” rating in a research note on Monday, April 27th. Ten equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, Oruka Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $134.30.

Oruka Therapeutics Price Performance

Shares of ORKA stock opened at $86.79 on Monday. The company has a market cap of $5.23 billion, a price-to-earnings ratio of -44.74 and a beta of -0.35. Oruka Therapeutics has a 1 year low of $12.84 and a 1 year high of $97.78. The firm has a fifty day moving average price of $70.54 and a 200-day moving average price of $51.50.

Oruka Therapeutics (NASDAQ:ORKA) last issued its quarterly earnings results on Wednesday, May 13th. The company reported ($0.48) EPS for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.04. Equities research analysts expect that Oruka Therapeutics will post -2.06 EPS for the current year.

Insider Transactions at Oruka Therapeutics

In other Oruka Therapeutics news, CEO Lawrence Otto Klein sold 1,729 shares of Oruka Therapeutics stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $69.69, for a total value of $120,494.01. Following the sale, the chief executive officer owned 925,580 shares of the company’s stock, valued at $64,503,670.20. The trade was a 0.19% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, SVP Arjun Agarwal sold 1,587 shares of the stock in a transaction that occurred on Monday, June 22nd. The shares were sold at an average price of $80.95, for a total value of $128,467.65. Following the transaction, the senior vice president owned 15,312 shares of the company’s stock, valued at $1,239,506.40. This represents a 9.39% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 185,407 shares of company stock worth $11,636,307. 23.49% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in ORKA. Viking Global Investors LP bought a new stake in shares of Oruka Therapeutics in the 3rd quarter valued at approximately $51,280,000. Paradigm Biocapital Advisors LP bought a new position in Oruka Therapeutics during the fourth quarter valued at $51,840,000. Remedium Capital Partners LLC bought a new stake in shares of Oruka Therapeutics in the 4th quarter worth about $47,054,000. Deep Track Capital LP boosted its stake in shares of Oruka Therapeutics by 38.4% during the 3rd quarter. Deep Track Capital LP now owns 2,654,781 shares of the company’s stock worth $51,051,000 after purchasing an additional 735,983 shares during the period. Finally, State Street Corp raised its position in Oruka Therapeutics by 112.2% in the 4th quarter. State Street Corp now owns 1,383,847 shares of the company’s stock worth $41,944,000 after purchasing an additional 731,819 shares during the period. Hedge funds and other institutional investors own 56.44% of the company’s stock.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a clinical?stage biopharmaceutical company focused on the development of novel peptide?based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell?permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.